Rehnberg, Johanna
Segelmark, Mårten
Ludvigsson, Jonas F.
Emilsson, Louise
Funding for this research was provided by:
Örebro University
Article History
Received: 24 October 2023
Accepted: 19 February 2024
First Online: 4 March 2024
Declarations
:
: The study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten), on the 31st of January 2022, approval number 2021-066629-01. Informed consent was deemed unnecessary by the ethics committee (Swedish Ethical Review Authority).
: Not applicable.
: Dr Rehnberg has obtained reinbursements for lectures from Astra Zeneca and Bayer. Dr Segelmark is a board member of the Swedish Renal Registry, he has received consultancy fees from Hansa Biopharma AB, Vifor Pharma and Astra Zeneca. Dr Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBERG) and that study has received funding from Janssen Corporation. Dr Ludvigsson has also received finacial support from MSD developing a paper reviewing national healthcare registers in China. Dr Ludvigsson is currently discussing potential research collaboration with Takeda. Dr Emilsson has no conflicts of interests.